In this study, we report on the use of GCC2 as a specific biomarker to distinguish between cancer-specific exosomes and normal cell-derived exosomes isolated from the body fluids of NSCLC patients, which can improve the diagnosis of cancer. Here, GCC2 is linked to non-small cell lung carcinoma.